Letter to the Editor Regarding “Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer”

We previously reported glioblastoma and unusual magnetic resonance imaging (MRI) findings in a patient previously treated for thyroid cancer with lenvatinib, a multitarget receptor tyrosine kinase (RTK) inhibitor.1 In that case, lenvatinib was likely to have affected both the radiologic and pathologic characteristics of the brain tumor, suggesting that brain tumors that develop during RTK treatment for other cancers may show atypical imaging characteristics.1 During patient follow-up, the MRI findings, which suggested tumor recurrence, were atypical and warrant being reported to underline our previous notion.

Source: World Neurosurgery - September 20, 2018 Category: Neurosurgery Authors: Nobuhiko Arai, Hirokazu Fujiwara, Hikaru Sasaki Tags: Letter to the Editor Source Type: research